Anti-PD-1/PD-L1 therapy has shown success in the treatment of liver cancer and may reverse immune tolerance in chronic hepatitis B (CHB). Aligos Therapeutics Inc. has presented preclinical data on the characterization of ALG-093940, a small molecule PD-1/PD-L1 inhibitor that induces PD-L1 dimerization and degradation.
GSK plc has announced a breakthrough in the treatment of chronic hepatitis B, reporting a functional cure rate of 19% across two phase III trials of its antisense oligonucleotide bepirovirsen.
As widely expected, GSK plc and Ionis Pharmaceuticals Inc. reported positive findings from two pivotal trials testing bepirovirsen in chronic hepatitis B, showing the antisense oligonucleotide therapy achieved a statistically and clinically meaningful functional cure rate, indicating a potential transition in CHB treatment beyond the current viral suppression-focused standard of care.
Nchroma Bio Inc. has received a certificate for clinical trial in Hong Kong to initiate a first-in-human phase I/II trial of CRMA-1001 for the treatment of chronic hepatitis B virus (HBV) infection. Dosing is expected to begin early next year.
In preclinical studies at Sunshine Lake Pharma Co. Ltd., researchers investigated the antiviral and immune-modulatory potential of HEC-191834, a novel and highly selective human Toll-like receptor 8 (TLR8) agonist, in chronic hepatitis B virus (HBV) models, as well as its activity when combined with siRNA.
Chronic infection with hepatitis B virus affects around a quarter of a billion people globally, and it can increase risk of cirrhosis and hepatocellular carcinoma. Such infection is typically treated with nucleoside analogues, which do not eliminate it entirely. Therefore researchers have been searching for effective vaccines that could work not only in the classical sense of preventing infection from becoming chronic, but also in a therapeutic sense of curing already chronic infection.
Ausperbio Therapeutics Inc. raised $110 million from two financing rounds in 2024 to advance its lead antisense oligonucleotide candidate as a functional cure for chronic hepatitis B.
Ausperbio Therapeutics Inc. raised $110 million from two financing rounds in 2024 to advance its lead antisense oligonucleotide candidate as a functional cure for chronic hepatitis B.
Researchers from presented preclinical data for AVX-70371, a novel therapeutic vaccine being developed for the treatment of chronic hepatitis B virus (HBV) infection.
SA-012 is an N-acetylgalactosamine (GalNAc) conjugated silencing RNA (siRNA) that targets the mRNA of the PD-L1 gene and is being developed by Suzhou Siran Biotechnology Co. Ltd. for the treatment of chronic hepatitis B (CHB).
